the aid library

LIST OPTIONS

Filter

14675

Sort by:

Direction:

Download (168)

View PDF (171)

Tool for the accreditation of research ethics committees

Pan American Health Organization PAHO (2023) C_WHO

The ethical governance of research assumes the existence of a national entity (or subnational if applicable, according to the constitution of a country) in charge of supervising the research ethics committees (RECs) that review and monitor research with human beings. This supervision includes the ac... more

Download (265)

View PDF (238)

A checklist for respiratory pathogen pandemic preparedness planning

World Health Organization WHO (2023) C_WHO

This checklist is an operational tool to help national authorities develop or revise national respiratory pathogen (inclusive of influenza and coronaviruses) pandemic preparedness plans.

Download (248)

View PDF (440)

WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions

World Health Organization (2019) C_WHO

It is estimated that more than 311 000 women die of cervical cancer each year. Of these deaths, 91% occur in low- and middle-income countries. Demographic changes and a lack of action mean that the number of deaths per year is projected to reach 460 000 by 2040.

Download (336)

View PDF (415)

User manual for WHO cervical cancer prevention and control costing tool: HPV vaccination module (‎C4P-HPV tool)

World Health Organisation (WHO) (2023) C_WHO

Cervical cancer is the fourth most common cancer in women worldwide in 2018, with 570,000 new cases and 311,000 deaths occurring annually.T he highest incidence rates are in Southern Africa, Eastern Africa, SubSaharan Africa, Western Africa, Melanesia, and Middle Africa . It also ranks as the leadin... more

Download (294)

View PDF (391)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (218)

View PDF (199)

A Roadmap to combat postpartum haemorrhage between 2023 and 2030

World Health Organization WHO (2023) C_WHO

WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths. Despite being preventable and treatable, PPH results in around 70 000 de... more

Download (248)

View PDF (227)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (143)

View PDF (156)

Tuberculosis in the WHO African Region: 2023 progress update - September 2023

World Health Organisation (WHO) (2023) C_WHO

This brief update on tuberculosis (TB) in the African region covers the state of TB in the WHO African region, strategic priorities and targets and the impact of COVID-19 on essential services. This is followed by key figures for the region, the role of WHO in country support and, recognizing the im... more

Download (176)

View PDF (189)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 10 August 2023

World Health Organization WHO (2023) C_WHO

Download (253)

View PDF (206)

Considerations for developing a national genomic surveillance strategy or action plan for pathogens with pandemic and epidemic potential

World Health Organization WHO (2023) C_WHO

Pathogen genomic surveillance has become a priority for public health systems in recent years. Genomic sequencing is increasingly being used to characterize pathogens and monitor important public health priorities (e.g. poliovirus, influenza virus, Mycobacterium tuberculosis and Vibrio cholerae, ant... more

Download (668)

View PDF (2663)

Organization of Case Management during a Cholera Outbreak

Global Task Force on Cholera Control (GTFCC) World Health Organisation (WHO) (2017) C_WHO

Cholera epidemics continue to be a major public health problem in many countries around the world. When epidemics strike, they can spread rapidly. The disease can also evolve quickly; patients with severe disease can die of dehydration hours after showing the first symptoms of cholera.

Download (185)

View PDF (197)

WHO initiative to stop the spread of Anopheles stephensi in Africa

World Health Organisation (WHO) (2023) C_WHO

Anopheles stephensi is a mosquito species that is capable of transmitting both Plasmodium falciparum and P. vivax malaria parasites. Unlike the other main mosquito vectors of malaria, it thrives in urban and man-made environments. Originally native to parts of South Asia and the Arabian Peninsula, A... more

Download (159)

View PDF (177)

Clinical management of COVID-19: Living guideline, 18 August 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO COVID-19 Clinical management: living guidance contains the most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is important.

Download (170)

View PDF (209)

WHO Global water, sanitation and hygiene: Annual report 2022

World Health Organisation (WHO) (2023) C_WHO

This report summarizes the World Health Organization’s (WHO) global work on water, sanitation and hygiene (WASH) during 2022. It describes how the Organization continued to deliver its essential WASH programming as elaborated in its 2018–2025 strategy.

Download (273)

View PDF (236)

Field Guide for Preparedness and Response to Diphtheria Outbreaks in the Western Pacific Region

World Health Organization WHO (2023) C_WHO

Due to high routine vaccination coverage, overall counts of diphtheria case have significantly declined in the Western Pacific Region recently. However, diphtheria is still prevalent in several countries and areas of the Region and remains a public health issue due to its high case fatality rate. ... more

Download (120)

View PDF (160)

Leprosy Programme and Transmission Assessment - Tool accompanying the Technical guidance on interruption of transmission and elimination of leprosy

World Health Organization WHO (2023) C_WHO

The Leprosy Programme and Transmission Assessment (LPTA) is an activity that is carried out by internal teams towards the end of Phase 1 (see Leprosy Elimination Framework in the Annex) when a subnational jurisdiction (typically second-tier) reaches the milestone for interruption of transmission, i.... more

Download (171)

View PDF (173)

SITREP N° 05 DU 22 au 23 JUILLET 2023 Épidémies de Choléra, Shigellose et Salmonellose au Congo

World Health Organisation (WHO) (2023) C_WHO

SITREP N° 05 DU 22 au 23 JUILLET 2023 Épidémies de Choléra, Shigellose et Salmonellose au Congo

Download (145)

View PDF (157)

Point-of-care tests for sexually transmitted infections: target product profiles

World Health Organisation (WHO) (2023) C_WHO

Despite the development of point-of-care diagnostic tests for syphilis, chlamydia, gonorrhoea, and trichomoniasis, none comply with all WHO criteria. This analysis overviews landscape analyses of point-of-care diagnostic technologies for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vagi... more

Download (177)

View PDF (167)

WHO report on the global tobacco epidemic, 2023: protect people from tobacco smoke

World Health Organisation (WHO) (2023) C_WHO

The ninth WHO report on the global tobacco epidemic tracks the progress made by countries in tobacco control since 2008 and, marks 15 years since the introduction of the MPOWER technical package which is designed to help countries implement the demand-reduction measures of the WHO Framework Conventi... more

Download (264)

View PDF (375)

Policies to protect children from the harmful impact of food marketing: WHO guideline

World Health Organisation (WHO) (2023) C_WHO

Children continue to be exposed to powerful food marketing, which predominantly promotes foods high in saturated fatty acids, trans-fatty acids, free sugars and/or sodium and uses a wide variety of marketing strategies that are likely to appeal to children. Food marketing has a harmful impact on chi... more